- Home
- Technology
- Services
- mRNA Display-based Antibody Discovery
- mRNA Display-based Peptide Discovery
- mRNA Display-based Protein Discovery
- Applications
- About
Bispecific antibodies can target two antigens or epitopes, and can simultaneously block or activate their mediated biological functions, or bring cells expressing two antigens close to each other, thereby enhancing the interaction between the two, and mediate a variety of specific biological effects with different mechanisms of action. CD BioSciences has many years of research experience in the field of antibody discovery, and is committed to providing bispecific antibodies discovery and screening services for customers around the world using its antibody discovery platform based on mRNA display.
Bispecific antibodies recognize and bind two different antigens or epitopes simultaneously. It can provide two effective action sites, and can be flexibly designed for different drug targets to achieve the effect of multi-target therapy. Due to its unique bifunctional structure and mechanism of action, bispecific antibodies can effectively enhance the binding specificity and targeting of antibodies to tumor cells, reduce side effects such as off-target, and the clinical cost is far lower than the combination of two single drugs. Therefore, it is regarded as a new generation of antibody therapy for tumor treatment. Furthermore, they also hold great promise in facilitating the targeted delivery of stem and progenitor cells for improved tissue regeneration. And in the past two decades, the application of complex molecular design and genetic engineering has solved many technical problems related to the preparation of double antibodies, such as: stability, solubility and other related parameters about druggable antibody molecules.
Fig. 1 Mechanisms and clinical study of three market BsAbs. (Ma, et al., 2021)
As a powerful and widely used approach for antibody discovery, the mRNA display library can quickly and efficiently identify and screen antibody fragments with high affinity for the target protein through the process of in vitro immune evolution. After sequence and functional identification, further antibodies constructed into different structures. Bispecific antibodies contain two different antigen-binding domains, which do not exist in nature and can only be produced artificially. Using mRNA display technology, a large-capacity antibody library can be constructed and single-domain antibodies against different targets can be screened out, and the screened high-affinity antibodies can be connected through appropriate linkers to construct bispecific antibodies.
CD BioSciences has built a high-throughput antibody discovery platform based on mRNA display technology, which can provide global customers with bispecific antibody discovery and screening services for different targets. Our antibody discovery platform generates large-capacity antibody display libraries by constructing random sequences, and can screen highly specific antibodies against different antigens, and then construct bispecific antibodies through appropriate linkers. Various targets can be screened, including but not limited to:
If you do not find a suitable option in our service, as long as you provide relevant target information, our expert team can customize the best solution for your project.
Various Forms
High Efficiency
High Throughput
Rich Experience
CD BioSciences has many years of project development experience in antibody discovery. Based on the mRNA display technology platform, it can provide customers with various types of antibody screening services. If you are interested in our services, please contact us for more details.
References
